Daily Sepsis Research Analysis
Three high-impact sepsis studies stood out today: a Swedish national cohort quantified long-term health-related quality of life (HRQoL) and work incapacity after ICU-treated sepsis, a prospective registry subanalysis identified a hemodynamic responder phenotype to polymyxin B hemoperfusion (PMX-HP) in refractory septic shock linked to markedly lower mortality, and a large MIMIC-IV cohort associated in-ICU statin exposure with reduced 28-day mortality. Together, they advance survivorship science,
Summary
Three high-impact sepsis studies stood out today: a Swedish national cohort quantified long-term health-related quality of life (HRQoL) and work incapacity after ICU-treated sepsis, a prospective registry subanalysis identified a hemodynamic responder phenotype to polymyxin B hemoperfusion (PMX-HP) in refractory septic shock linked to markedly lower mortality, and a large MIMIC-IV cohort associated in-ICU statin exposure with reduced 28-day mortality. Together, they advance survivorship science, precision adjunct therapy selection, and drug repurposing.
Research Themes
- Sepsis survivorship and long-term outcomes
- Precision adjunctive therapies and extracorporeal support in septic shock
- Drug repurposing and anti-inflammatory modulation in sepsis care
Selected Articles
1. Health-related quality of life and functional recovery after intensive care for sepsis in a national cohort.
In a Swedish national cohort of 14,006 ICU-treated sepsis survivors, health-related quality of life (RAND-36) was lower than population norms but improved over time, while work incapacity (sick leave) remained elevated and correlated with lower HRQoL. Comorbidities and longer ICU/hospital length of stay, rather than acute severity, were key drivers of poorer patient-centered outcomes.
Impact: This is one of the largest national assessments linking sepsis survivorship with both subjective HRQoL and objective work incapacity, identifying modifiable targets for post-ICU care.
Clinical Implications: Incorporate routine HRQoL assessment and vocational support into sepsis survivorship clinics, targeting patients with multiple comorbidities and prolonged length of stay for rehabilitative and psychosocial interventions.
Key Findings
- RAND-36 HRQoL scores in 14,006 sepsis ICU survivors were below population norms but improved with time after discharge.
- Comorbidities and longer ICU/hospital length of stay correlated with lower HRQoL; invasive ventilation associated with higher HRQoL, whereas CRRT and longer LOS were negative.
- Sick leave was high before sepsis (pre-existing vulnerability), increased further after ICU, and did not return to baseline; greater sick leave correlated with lower HRQoL.
Methodological Strengths
- Nationwide cohort with large sample size and registry linkage
- Use of both patient-reported HRQoL (RAND-36) and objective sick-leave metrics
Limitations
- Observational design with potential residual confounding and selection/response bias in HRQoL surveys
- Exact timing and frequency of follow-up assessments varied across the cohort
Future Directions: Prospective interventional studies to test bundled post-ICU rehabilitation, mental health, and vocational programs targeted to high-risk sepsis survivors identified by comorbidity and LOS.
INTRODUCTION: Functional recovery after intensive care is an important patient-centered outcome. In this study, we investigated risk factors for poor outcome after intensive care for sepsis using serial health-related quality of life (HRQoL) assessments and the burden of work incapacity as an objective proxy for functional recovery. METHODS: We acquired data on all adult intensive care unit (ICU) patients with sepsis in Sweden between 2008 and 2020. Primary outcome was HRQoL assessed with RAND-36 at follow-up after ICU discharge. Sick-leave information was acquired on the working-age subpopulation to assess the burden of work incapacity. RESULTS: RAND-36 data were available for 14,006 individuals and was lower than Swedish population reference levels. Males had higher RAND-36. Age had varying associations. Pre-ICU comorbidities were associated with lower RAND-36, whereas severity of illness was associated with lower general health. Invasive ventilation was associated with higher RAND-36, while continuous renal replacement therapy and length of stay (LoS) were associated with lower RAND-36. RAND-36 increased with time after ICU. Sick-leave length was associated with lower RAND-36. High levels of sick leave were seen in patients before intensive care for sepsis, suggesting pre-existing vulnerability. Sick leave increased further after sepsis and did not return to baseline, suggesting incomplete functional recovery, with lower education, female sex, and comorbidities as risk factors. CONCLUSIONS: In conclusion, in a Swedish national cohort of ICU patients surviving sepsis, HRQoL was low but improved over time. Severity of illness had minimal impact on HRQoL, while LoS and comorbidities were negative factors. Functional recovery in the form of days on sick leave showed a similar pattern. STUDY REGISTRATION: The study was registered with clinicaltrials.gov: NCT06368336, on the 15th of April 2024.
2. HEMODYNAMIC RESPONSE BY POLYMYXIN B HEMOPERFUSION AND ITS CLINICAL OUTCOMES IN PATIENTS WITH REFRACTORY SEPTIC SHOCK: A POST-HOC SUBANALYSIS OF PROSPECTIVE COHORT STUDY.
In a predefined subanalysis of a prospective registry, 65% of refractory septic shock patients receiving PMX-HP achieved a hemodynamic response (≥20% reduction in vasopressor dependency index within 6 h), which was associated with markedly lower 28-day mortality (8% vs 31%). Lower SOFA (≤10), abdominal/urinary source, and higher baseline vasopressor dependency predicted response.
Impact: Defines a pragmatic, early hemodynamic response metric linked to survival and identifies bedside predictors to select PMX-HP candidates, advancing precision use of an often-debated therapy.
Clinical Implications: Consider PMX-HP in refractory septic shock patients with lower SOFA (≤10), abdominal/urinary source, and high vasopressor dependency, monitoring for ≥20% improvement in the vasopressor dependency index within 6 hours to guide continuation.
Key Findings
- Hemodynamic response (≥20% vasopressor dependency improvement in 6 h) occurred in 65% of PMX-HP patients.
- 28-day mortality was 8% in responders vs 31% in nonresponders (P=0.0042).
- Predictors of response: SOFA score ≤10 (aOR 3.36), abdominal/urinary infection source (aOR 2.49), and baseline vasopressor dependency index ≥0.5 mmHg−1 (aOR 2.14).
Methodological Strengths
- Prospective registry with predefined subanalysis and standardized hemodynamic metric
- Clinically meaningful endpoint (28-day mortality) and registered protocol
Limitations
- Non-randomized design with potential confounding by indication
- Single-country registry and relatively small PMX-HP sample (n=82) limit generalizability
Future Directions: Biomarker- and phenotype-guided randomized trials to validate response-based PMX-HP selection and to test protocolized continuation/cessation criteria.
Background: Polymyxin B hemoperfusion (PMX-HP) reportedly improves hemodynamic status in some but not all patients with septic shock. We examined the association between hemodynamic response and clinical outcomes and explored factors that may identify patients with hemodynamic response. Methods: BEAT-SHOCK registry is a prospective cohort study of 309 consecutive adult patients with septic shock requiring high-dose norepinephrine. This predefined subanalysis included 82 patients treated with PMX-HP. We defined hemodynamic response as a ≥ 20% improvement within 6 h of starting PMX-HP in the modified vasopressor dependency index, representing vasopressor dosage divided by mean arterial pressure. Results: The median modified vasopressor dependency index at the start of PMX-HP was 0.56 mmHg -1 , and 0.34 mmHg -1 6 h after starting PMX-HP (median relative change -32%). Hemodynamic response was obtained in 53 patients (65%; responder group). The 28-day mortality rate was 8% (4/53) in the responder group and 31% (9/29) in the nonresponder group ( P = 0.0042). Three potential factors were: lower Sequential Organ Failure Assessment score (≤10, adjusted odds ratio [aOR] 3.36), abdominal or urinary tract infection (aOR 2.49), and higher modified vasopressor dependency index at the start of PMX-HP (≥0.5 mmHg -1 , aOR 2.14). Patients with two or three factors were likely to respond to PMX-HP. Conclusions: Among patients with refractory septic shock, 65% had hemodynamic response after PMX-HP, and it was associated with better clinical outcomes, as shown by the higher survival rate. The number of the following factors was associated with the likelihood of hemodynamic response: less organ dysfunction, more vasopressors, and abdominal/urinary tract infection. Trial registration: UMIN Clinical Trial Registry on 1 November 2019 (registration no. UMIN000038302).
3. Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.
In a 20,230-patient MIMIC-IV cohort, statin exposure during ICU stay was associated with lower 28-day mortality after propensity score matching (14.3% vs 23.4%; HR 0.56) and reductions in ICU and in-hospital mortality. Effects were consistent across subgroups, supporting further prospective evaluation of statins as adjunctive therapy in sepsis.
Impact: The large, rigorously matched cohort provides compelling real-world evidence for a widely available therapy with strong biological plausibility in sepsis.
Clinical Implications: For patients already on statins or without contraindications, consider continuation/early re-initiation during ICU care while awaiting trial results; monitor for hepatic and myopathic adverse effects.
Key Findings
- After PSM (n=6,070 per group), 28-day mortality was lower with statins (14.3% vs 23.4%; HR 0.56, 95% CI 0.52–0.61).
- Statin use was associated with reduced ICU mortality (OR 0.43) and in-hospital mortality (OR 0.50).
- Benefits were consistent across diverse patient subgroups and robust in sensitivity analyses.
Methodological Strengths
- Very large sample size with propensity score matching and multivariable adjustments
- Consistent findings across subgroups and sensitivity analyses
Limitations
- Retrospective design with potential residual confounding and treatment-by-indication bias
- Exposure heterogeneity (timing, dose, statin type) not fully controlled
Future Directions: Pragmatic randomized trials testing continuation/initiation strategies, dose, and statin class; biomarker-enriched designs to identify responders.
BACKGROUND: Despite early goal-directed therapy, sepsis mortality remains high. Statins exhibit pleiotropic effects, including anti-inflammatory and antimicrobial properties, which may be beneficial during sepsis. OBJECTIVE: To determine whether statins could improve the clinical outcomes in patients with sepsis. METHODS: We conducted a retrospective cohort study using data from the Medical Information Mart in Intensive Care-IV (MIMIC-IV) database. Adult patients with sepsis were included in the analysis. The exposure factor of this study was statin use during the Intensive Care Unit (ICU) stay. The primary outcome was 28-day all-cause mortality. The secondary outcomes were ICU and in-hospital mortality, length of ICU stay and hospital stay, duration of mechanical ventilation (MV) and continuous renal replacement therapy (CRRT). Both propensity score matching (PSM) and stepwise regression analyses were employed to adjust for potential confounders. RESULTS: The unmatched cohort comprised 20230 eligible patients, with 8972 patients in the statin group and 11258 in the no statin group. Propensity score matching generated balanced cohorts with 6070 patients in each group. Post-PSM analysis revealed significantly lower 28-day all-cause mortality in the statin group (14.3% [870/6070]) compared to the no statin group (23.4% [1421/6070]). Statin use was associated with decreased 28-day all-cause mortality (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.52-0.61; p < 0.001). In subgroup analysis, this beneficial effect was consistent across the different baseline characteristics of patients. Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). Sensitivity analysis using the unmatched cohort also showed a significant difference in 28-day all-cause mortality between the statin group and the no statin group (HR, 0.56; 95% CI, 0.52-0.61; p < 0.001). CONCLUSION: Statins were associated with decreased mortality in critically ill patients with sepsis. Further high-quality prospective studies are still needed to verify our findings.